drugset / Trial / NCT02603432

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

NCT02603432

Phase 3 Completed 700 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.

Timeline

Start
2016-04-25
Primary completion
2019-10-21
Completion
2023-03-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Avelumab Monoclonal antibody 10 mg/kg Intravenous

Indications